Researchers at Weill Cornell Medicine and the Cornell University College of Veterinary Medicine have undertaken an ambitious $5 million project to create new model systems that accurately reflect the biology, genetics and tumor-host interactions of difficult-to-treat blood cancers. Read more
Thousands of hematologists gathered in San Diego on Dec. 3 for the 58th Annual Meeting of the American Society of Hematology (ASH), and Weill Cornell Medicine/NewYork-Presbyterian was well represented. Read more
Infectious complication rates following prostate biopsies continue to increase, despite decreased use of the procedures, according to Jim Hu, M.D. Read more
A multidisciplinary team led by Ithaca member Mingming Wu has devised a method for measuring the force a breast cancer cell exerts on its fibrous surroundings. Read more
Lipstick Angels, a non-profit that brings volunteer makeup artists into hospitals to treat them with facials, makeovers and massage treatments has started a program at NewYork-Presbyterian. Read more
An innovative clinical trial at Weill Cornell Medicine has helped Ralph Hills recover from an aggressive leukemia - without ever being admitted to the hospital. Read more
Findings from a highly anticipated, randomized, phase II trial could possibly pave the path for the FDA approval of the first targeted therapy for patients with triple-negative breast cancer (TNBC), explains Linda T. Vahdat, M.D. Read more
A team led by Doug Fearon, M.D., has traced cachexia to a molecular reprogramming of the liver induced by tumors, which also releases stress hormones that can prevent the immune system from responding. Read more